These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32227166)

  • 1. Febuxostat and atrial fibrillation.
    Kuwabara M; Borghi C; Johnson RJ
    Eur Heart J; 2020 Aug; 41(30):2916-2917. PubMed ID: 32227166
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
    Singh JA; Cleveland JD
    Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
    Alten R; Mischkewitz M; Nitschmann S
    Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
    [No Abstract]   [Full Text] [Related]  

  • 4. Confounding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
    Hsu PK; Lee YH; Wei JCC
    Ann Rheum Dis; 2022 Jul; 81(7):e122. PubMed ID: 32561600
    [No Abstract]   [Full Text] [Related]  

  • 5. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.
    Pawar A; Desai RJ; Liu J; Kim E; Kim SC
    J Am Heart Assoc; 2021 Apr; 10(7):e020045. PubMed ID: 33764153
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu
    Singh JA
    Ann Rheum Dis; 2022 Jul; 81(7):e123. PubMed ID: 32561601
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
    Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
    Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
    Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
    Ma KS; Wei JC; Chung WH
    Ann Rheum Dis; 2022 Jun; 81(6):e107. PubMed ID: 32561605
    [No Abstract]   [Full Text] [Related]  

  • 13. In older adults, new use of allopurinol or febuxostat was linked to hypersensitivity reactions versus colchicine.
    Schattner A
    Ann Intern Med; 2020 Jul; 173(2):JC10. PubMed ID: 32687746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma
    Singh JA
    Ann Rheum Dis; 2022 Jun; 81(6):e108. PubMed ID: 32561599
    [No Abstract]   [Full Text] [Related]  

  • 16. Febuxostat in the management of gout: a cost-effectiveness analysis.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gout: Why compare the effectiveness of suboptimal gout management?
    Dalbeth N; Stamp LK
    Nat Rev Rheumatol; 2015 Sep; 11(9):506-7. PubMed ID: 26150126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
    Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
    Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
    Bardin T; Chalès G; Pascart T; Flipo RM; Korng Ea H; Roujeau JC; Delayen A; Clerson P
    Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gout Medication Receives Black Box Warning.
    Aschenbrenner DS
    Am J Nurs; 2019 Jun; 119(6):24-25. PubMed ID: 31135425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.